Paper
Simvastatin potentiates the anti-hepatitis B virus activity of FDA-approved nucleoside analogue inhibitors in vitro.
Published Jun 1, 2010 · T. Bader, B. Korba
Antiviral research
Q1 SJR score
51
Citations
3
Influential Citations
Abstract
Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.
In Vitro StudyStudy Snapshot
Simvastatin, a statin, shows strong in vitro anti-hepatitis B virus activity when combined with FDA-approved nucleoside analogue inhibitors, potentially enhancing anti-HBV therapy in clinical settings.
PopulationOlder adults (50-71 years)
Sample size24
MethodsObservational
OutcomesBody Mass Index projections
ResultsSocial networks mitigate obesity in older groups.
Sign up to use Study Snapshot
Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.
Full text analysis coming soon...
References
Statins potentiate the in vitro anti‐hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development
Combining specific HCV inhibitors with statins may result in a more profound antiviral effect and delay or prevent resistance development.
2009·116citations·Leen Delang et al.·Hepatology
Hepatology
Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial.
Simvastatin decreases portal pressure and improves liver perfusion in patients with cirrhosis, with additive effects when combined with beta-adrenergic blockers.
2009·387citations·J. Abraldes et al.·Gastroenterology
Gastroenterology
Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes.
Statin use significantly reduces the risk of hepatocellular carcinoma in patients with diabetes.
2009·264citations·H. El‐Serag et al.·Gastroenterology
Gastroenterology
Effects of statins on the secretion of human serum albumin in cultured HepG2 cells
Simvastatin treatment increases serum albumin secretion in cultured HepG2 cells, suggesting another potential benefit in preventing cardiovascular disease by stimulating HSA biosynthesis.
2009·24citations·C. Ha et al.·Journal of Biomedical Science
Journal of Biomedical Science
Fluvastatin Inhibits Hepatitis C Replication in Humans
Fluvastatin shows modest, variable, and short-lived suppressive effects against hepatitis C in humans, supporting potential for combined treatment with standard therapy.
2008·198citations·T. Bader et al.·The American Journal of Gastroenterology
The American Journal of Gastroenterology
Citations
Statins in Chronic Liver Disease: Review of the Literature and Future Role
Statins show potential in chronic liver disease prevention and treatment, with their largest impact likely in chemoprevention, and their role in precision hepatology needs further exploration.
2024·0citations·Nguyen V. Pham et al.·Seminars in Liver Disease
Seminars in Liver Disease
Assessment of Hepatoprotective Consequence of Alpinia galanga Extract against Ethanol and Carbon Tetrachloride Induced Liver Damage on Experimental Animal
Alpinia galanga aqueous extract shows potential as a hepatoprotective agent against alcohol and carbon tetrachloride-induced liver damage in male Wistar rats.
2024·0citations·Archita Srivastava et al.·Research Journal of Pharmacology and Pharmacodynamics
Research Journal of Pharmacology and Pharmacodynamics
Oncogenic viruses and host lipid metabolism: a new perspective.
Oncogenic viruses alter host lipid metabolism, leading to altered requirements and potential new antiviral agents and therapeutic targets.
2023·2citations·Zhiyuan Gong et al.·The Journal of general virology
The Journal of general virology
The Association between Statins and Liver Cancer Risk in Patients with Heart Failure: A Nationwide Population-Based Cohort Study
Statins may decrease liver cancer risk in patients with heart failure, with both lipophilic and hydrophilic statins showing significant reductions.
2023·3citations·Meng-Chuan Lu et al.·Cancers
Cancers
Atorvastatin Rapidly Reduces Hepatitis B Viral Load in Combination with Tenofovir: A Prospective Clinical Trial
Atorvastatin combined with tenofovir effectively reduces hepatitis B viral load and is a safe combination therapy for chronic hepatitis B patients.
2022·8citations·M. Gharehbeglou et al.·The Canadian Journal of Infectious Diseases & Medical Microbiology = Journal Canadien des Maladies Infectieuses et de la Microbiologie Médicale
The Canadian Journal of Infectious Diseases & Medical Microbiology = Journal Canadien des Maladies Infectieuses et de la Microbiologie Médicale
Viral Hepatitis, Cholesterol Metabolism, and Cholesterol-Lowering Natural Compounds
Cholesterol-lowering drugs show promise in treating viral hepatitis, with potential applications in treating HBV and HCV infections.
2022·27citations·J. Liou et al.·International Journal of Molecular Sciences
International Journal of Molecular Sciences
Statin and aspirin for chemoprevention of hepatocellular carcinoma: Time to use or wait further?
Statin and aspirin therapy show potential in chemoprevention of hepatocellular carcinoma, but current evidence is limited and randomized controlled trials are needed for further investigation.
2022·17citations·M. Goh et al.·Clinical and Molecular Hepatology
Clinical and Molecular Hepatology
Anti-flavivirus Properties of Lipid-Lowering Drugs
Lipid-lowering drugs show potential as safe, host-targeted antivirals for treating flavivirus infections like dengue and zika.
2021·22citations·Carlos Noe Farfán-Morales et al.·Frontiers in Physiology
Frontiers in Physiology
Lipid homeostasis and mevalonate pathway in COVID-19: Basic concepts and potential therapeutic targets
Lipid homeostasis and mevalonate pathway targeting are valid approaches to rapidly neutralize viruses, potentially aiding in the reduction of SARS-CoV-2 morbidity and mortality.
2021·23citations·M. Proto et al.·Progress in Lipid Research
Progress in Lipid Research